Complement-Dependent Cytotoxicity (CDC) Crossmatch for T and B Cells and Auto Crossmatch

• Test Name: Complement-Dependent Cytotoxicity (CDC) Crossmatch for T and B Cells and Auto Crossmatch
• Purpose: Determines compatibility between donor and recipient by detecting pre-existing antibodies against donor T and B lymphocytes.
• Principle: Uses patient serum to assess cytotoxicity against donor lymphocytes in the presence of complement.
• Sample Type: Serum from recipient and lymphocytes from donor.
• Methodology: CDC assay involving incubation of recipient serum with donor lymphocytes and complement, followed by cell viability assessment.

• Transplant Compatibility: Essential for pre-transplant evaluation to ensure immunologic compatibility.
• Antibody Detection: Identifies pre-existing anti-donor antibodies that can cause graft rejection.
• Immune Monitoring: Assesses the recipient’s immune response towards donor antigens.
• Risk Assessment: Evaluates the risk of hyperacute or acute rejection post-transplant.
• Immunosuppression Guidance: Helps in planning the immunosuppressive therapy required for transplant patients.

• T Cell Crossmatch: Evaluates cytotoxicity against donor T lymphocytes.
• B Cell Crossmatch: Assesses cytotoxicity against donor B lymphocytes.
• Auto Crossmatch: Measures recipient’s serum reactivity against their own cells to rule out autoantibodies.
• Complement Addition: Involves the addition of complement to facilitate cytotoxic reaction.
• Viability Assessment: Utilizes dyes such as Trypan blue or eosin Y to assess cell viability post-reaction.

• Negative Crossmatch: No significant cytotoxicity; indicates compatibility between donor and recipient.
• Positive Crossmatch: Significant cytotoxicity; indicates presence of anti-donor antibodies, suggesting incompatibility.
• Auto Crossmatch: Positive result may indicate autoantibodies or non-specific reactivity.
• T Cell Specificity: Positive T cell crossmatch suggests potential for cellular rejection.
• B Cell Specificity: Positive B cell crossmatch indicates potential for humoral rejection.

• Positive Result: Indicates presence of donor-specific antibodies (DSA); high risk for graft rejection.
• Negative Result: Suggests absence of DSA; lower risk for rejection and better graft survival.
• Equivocal Result: Unclear; may require additional testing or repeat crossmatch.
• Auto Crossmatch Positive: Indicates autoantibodies; requires further investigation.

Q: What is the purpose of the CDC Cross Match T B Cells and Auto Crossmatch test?
The test assesses compatibility between a transplant donor and recipient by detecting pre-existing antibodies that could cause rejection
 

Q: How is the CDC Cross Match test performed?
The test involves incubating the recipient’s serum with donor lymphocytes in the presence of complement, followed by assessing cell viability to detect cytotoxicity
 

Q: What samples are required for the CDC Cross Match test?
The test requires serum from the transplant recipient and lymphocytes from the donor
 

Q: What does a positive crossmatch result indicate?
A positive result indicates the presence of anti-donor antibodies, suggesting a high risk of transplant rejection
 

Q: Can the CDC Cross Match test predict transplant success?
Yes, a negative crossmatch result generally indicates a higher likelihood of transplant success and lower risk of rejection
 

Q: What is the significance of a positive auto crossmatch?
A positive auto crossmatch may indicate the presence of autoantibodies or non-specific reactivity, necessitating further investigation
 

Q: How do the results of the CDC Cross Match test influence transplant decisions?
The results guide the selection of compatible donors and help in planning the immunosuppressive therapy to reduce the risk of rejection